Chronic adverse effects from anti-PD-1 immunotherapies common
Response to one COVID-19 vaccine dose strong in previously infected
16 April 2021New understanding of the deleterious immune response in rheumatoid arthritis
16 April 2021Chronic adverse effects from anti-PD-1 immunotherapies common
(HealthDay)—Chronic immune-related adverse effects after adjuvant treatment with anti-programmed cell death 1 (anti-PD-1) immunotherapies for melanoma are more common than previously thought, according to a study published online March 25 in JAMA Oncology.
